Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders
Authors:
- 27 May 2020
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 34 (8) , 841-852
Abstract
Antipsychotic long-acting injections improve relapse prevention in psychotic disorders. Three new risperidone formulations have been developed that offer advantages over currently available risperidone-based long-acting injections. Risperidone ISM® is a monthly intramuscular injection that does not require loading doses or concurrent oral risperidone. RBP-7000 is a monthly subcutaneous injection not requiring loading or oral supplementation. BB0817 is a 6-monthly implant of risperidone injected subcutaneously. All three preparations have been shown to be effective and well tolerated in clinical trials. A fourth formulation (TV-46000), which can be given subcutaneously every 1 or 2 months, has recently begun trials.Keywords
This publication has 40 references indexed in Scilit:
- A model‐based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP‐7000, a new, long‐acting, sustained‐released formulation of risperidoneThe Journal of Clinical Pharmacology, 2013
- Injectable In Situ Forming Microparticles: A Novel Drug Delivery SystemTropical Journal of Pharmaceutical Research, 2012
- Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trialBMC Psychiatry, 2011
- Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with SchizophreniaClinical Pharmacokinetics, 2009
- Risperidone long‐acting injection: a 6‐year mirror‐image study of healthcare resource useActa Psychiatrica Scandinavica, 2009
- Risperidone Long-Acting InjectionThe Journal of Clinical Psychiatry, 2008
- Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia☆Schizophrenia Research, 2008
- Establishing a dose–response relationship for haloperidol decanoatePsychiatric Bulletin, 2005
- Clinical review of a long-acting, injectable formulation of risperidoneClinical Therapeutics, 2004
- Long-acting risperidone: Prolonged-release injectable delivery of risperidone using medisorbò microsphere technologySchizophrenia Research, 2003